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Abbreviations DOX, doxorubicin; SLC, single-layered cells; MCTS, multicellular tumour spheroid; PBS, phosphate buffer saline; n, cell layer number from the centre of the MCTS to the periphery; m, total number of cell layers in the MCTS; D, administered drug dose outside the MCTS; D n , drug exposure dose outside the n th cell layer of the MCTS; C n , intracellular concentration of drug in the n th cell layer of the MCTS; K n , the transport rate constant across the membranes of the cells in the n th layer of the MCTS; P n , permeability coefficients across the membranes of the cells in the n th layer of the MCTS; K pn , drug penetration rate within the intercellular space of the n th cell layer of the MCTS; X mn , intracellular drug concentration threshold in the n th cell layer of the MCTS; dCn dt , intracellular retention rate in the n th cell layer of the MCTS; dDn dt , intercellular diffusion rate outside the n th cell layer of the MCTS; F n , florescence intensity of the n th cell layer of the MCTS; V cell , the volume of a single cell; D cell , the diameter of a single cell; N n , cell count in the n th cell layer of the MCTS; M spheroid , moles of drugs in the whole MCTS; D 0 , plasma drug concentration; R, average xenograft radius; m 0 , total cell layer number inside the xenograft; C 0 n , intracellular drug concentration drug in the n th cell layer of tumours; K 0 n , transport rate constant across the membranes of the cells in the n th layer of tumours; P 0 n , permeability coefficients across the membranes of the cells in the n th layer of tumours; K 0 pn , drug penetration rate within the intercellular space of the n th cell layer of tumours; X 0 mn , intracellular drug concentration threshold in the n th cell layer of tumours; dC 0 n
Introduction
The abnormal architecture and composition of solid tumours, especially for those tumour cells in poorly perfused regions (avascular regions), limit the uptake and distribution of antitumour drugs and thus generate treatment resistance (Jain, 2013; Al-Abd et al., 2015) . Although a series of 'promoter drugs' designed to improve drug supply from the vascular system have been tested (Marcucci and Corti, 2012) , their effects seem to be limited not only temporally but also spatially (Cesca et al., 2009; Pastuskovas et al., 2012; Van der Veldt et al., 2012) . After leaking out of the vasculature, chemotherapeutic agents still must penetrate deeply into tumour cells in avascular regions (Huang et al., 2015) . Thus, for chemotherapeutic treatment to be effective, improving drug delivery to the avascular regions of tumours is essential.
Although doxorubicin has a broad spectrum of antitumour activity, the inhomogeneous penetration profile of doxorubicin often compromises its therapeutic effect (Ma and Mumper, 2013; Agudelo et al., 2016) . To date, several approaches and strategies focused on regulating intercellular diffusion and cell internalization have been developed to improve the penetration ability of doxorubicin. However, whether these efforts allow for the efficient transport of doxorubicin into core tumour cells remains in doubt (Agudelo et al., 2016) . Despite the improvement in the intercellular penetration of encapsulated doxorubicin by PEG shielding, the resulting poor cell internalization limited drug efficacy (Kim et al., 2010; Zhang et al., 2015) . Target ligand decoration improved target cell internalization but did not affect or even negatively affected intratumoural localization (van der Meel et al., 2013) . These results indicated that intercellular diffusion and intracellular retention are two independent but inseparable processes that together govern DOX delivery in the avascular regions of tumours. Therefore, focusing on only one of them might fail to improve doxorubicin-related delivery (Zhang et al., 2015) .
The most commonly used method for evaluating penetration in the avascular regions of tumours is based on fluorescence imaging (Ma et al., 2012; Ren et al., 2016) . However, this imaging approach could reveal only the penetration depth, failing to provide the intercellular and intracellular kinetics, let alone the dynamic interaction between these two aspects (Kim et al., 2013) . Mathematical models are uniquely advantageous for describing and elucidating complex kinetic profiles (Hicks et al., 2003; Evans et al., 2009; Lu et al., 2015) . Although there is a wealth of mathematical modelling of the drug penetration profile of macromolecular drugs in the avascular region of tumours (Goodman et al., 2008; Thurber and Wittrup, 2008; Thurber et al., 2008b; Chou et al., 2013; Vasalou et al., 2015) , only a limited number of studies have focused on low MW drugs. Richard et al. quantitatively measured the actual diffusion coefficient of vinblastine in multicellular layers (MCL) according to the Fickian diffusion model but did not consider the effect of cellular uptake (Modok et al., 2006) . In our previous studies, a compartment-based mathematical model was successfully applied to evaluate doxorubicin cellular uptake in single-layered cells (SLC) (Zhang et al., 2012) . However, this model is not able to evaluate drug penetration. A model that coupled intracellular accumulation and intercellular diffusive was investigated by Jackson (2003) but this model considered cell clusters as a whole entity and thus could not reflect the heterogeneity of intracellular drug accumulation in different regions. Smye et al. established a multi-compartment model to describe doxorubicin penetration and intracellular uptake into different cell layers through MCL. However, in this analysis all parameters across the layers were predefined as being equal in value, thus disregarding the actual parameter changing profiles (Evans et al., 2009) .
In this study, an innovative individual-cell-based drug penetration model based on multicellular tumour spheroids (MCTSs) was developed, and all kinetic parameters would be simulated based on the experimental data to reflect the actual kinetic characteristics. MCTSs (>500 μm in diameter), which are superior to MCL, displayed physiochemical gradients similar to micrometastases and avascular tumours of a certain size, making them an ideal model for reflecting the heterogeneity of tumour cells and the micro-environments around tumour cells (Mehta et al., 2012) . Furthermore, this method treated single cells in different cell layers as independent units and modelled the intracellular accumulation in different cells according to a compartment model. Compartment models have been widely applied to doxorubicin penetration and accumulation (Jackson, 2003; Evans et al., 2009; Sinek et al., 2009; Zhang et al., 2012) , and we chose to extend our model using the model of Zhang et al. (2012) to account for doxorubicin accumulation in different cell layers of MCTSs. We noted that in this context, this model was advantageous over other compartment models because the kinetic parameters could reflect both the passive and active transport of doxorubicin. Drug penetration profiles can be expressed with partial differential equations (PDEs) (Ward and King, 2003) , ordinary differential equations (ODEs) (Goodman et al., 2008) or even a coupled ODE-PDE model (Eikenberry, 2009) . We chose ODEs instead of PDEs because PDEs rendered calculating the exact values of different parameters in MCTS almost impossible. After solving differential equations and estimating parameters, we first quantitatively described the kinetic profiles of doxorubicin penetration and retention in different cell layers and then the underlying effects of pathophysiological factors were then described from a mathematical viewpoint. Secondly, we compared the different effects of an efflux inhibitor (LY335979) (Dantzig et al., 1996) and a hypoxia inhibitor (YC-1) (Shin et al., 2007) on our model to provide a quantitative description and evaluation of the rules for the efficient deep penetration of doxorubicin-related delivery. Finally, the mathematical model was further applied to evaluate the penetration of INNO 206, the first experimental pHresponsive, doxorubicin derivative in clinical trials (Kratz, 2007) .
Methods

Monolayer cell culture
Human hepatoma cells (HepG2) were obtained from American Type Culture Collection and cultured in complete DMEM supplemented with 10% fetal bovine serum and 100 U·mL À1 penicillin and streptomycin (Life Technologies, Carlsbad, CA, USA) at 37°C with 5% CO 2 . The medium was changed every 2 days.
Formation of multicellular tumour spheroid (MTCS)
HepG2 MCTSs were developed using the 3D non-scaffold-based cell culture system (Costa et al., 2016) . Agarose-coated 96-well plates were prepared as follows: 2% (w/v) agarose was dissolved in DMEM, heated and sterilized at 121°C for 15 min and then dispensed into single wells (60 μL per well). Trypsinized HepG2 cells were seeded into each well at a density of 7500 cells per well, incubated at 37°C with 5% CO 2 and fed every 3 days by carefully replacing half of the spent medium with the same amount of fresh medium. After 7 days, the uniform and compact MCTSs were selected for the following studies.
Animals
All animal care and experimental procedures were conducted according the National Research Council's Guidelines for the care and use of laboratory animals and were approved by the Animal Ethics Committee at China Pharmaceutical University (Nanjing, Jiangsu, China). Every effort was made to minimize animal pain, suffering and distress and to reduce the number of animals used. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015 
Immunohistochemical assay
MCTSs were fixed in 4% paraformaldehyde overnight, embedded in paraffin and then cut into 4 μm serial sections. Tumour tissues were fixed in 4% paraformaldehyde overnight, processed with gradient concentrations of sucrose solution, washed by PBS, embedded immediately in optimum cutting temperature (OCT) compound (Sakura, CA, USA) and frozen at À80°C for 1 h prior to tissue sectioning. The tumour sections were cut at a thickness of 10 μm. MCTS sections and tumour sections were stained with H&E and Ki-67 or with a specific antibody. The diameter and cell layer number of the MCTSs were quantified using Leica Qwin Lite (Leica, Germany).
Scanning electron microscopy assay
After 7 days of incubation, the morphology of HepG2 MCTSs was analysed in detail with a scanning electron microscope (SEM). After being rinsed with PBS, samples were fixed in 2% glutaraldehyde (Carl Roth GmbH & Co KG, Karlsruhe, Germany) overnight, washed with cacodylate buffer and incubated with 1% osmium tetroxide for 1 h. Then, spheroids were washed and dehydrated in an ascending ethanol series, followed by critical point drying with hexamethyldisilazane (HMDS, Alfa Aesar, Karlsruhe, Germany). Finally, the spheroids were transferred to conductive carbon adhesive tabs, sputtered with gold and analysed with the SEM (HITACHI S-3000N, Tokyo, Japan). (Friedrich et al., 2007) and a CCK-8 assay kit (KeyGEN BioTech, Nanjing, China). At each drug concentration, the cell viabilities were quantified relative to those in wells without drugs, and the IC 50 values were calculated based on the Bliss method.
Cellular retention assay
After different times of incubation with drug, SLC and MCTSs were rinsed with cold PBS and lysed by three freeze-thaw cycles. Protein concentrations were measured by the method of Bradford, and doxorubicin concentration was determined by LC-MS/MS (Zhang et al., 2012) . HSA-INNO 206 was synthesized according to the method given in Boga et al. (2009) . Our unpublished data further showed that albuminbound INNO 206 was stable in methanol with <8% hydrazone linker broken. Released unbound doxorubicin concentration in HSA-INNO 206 administration group could be directly determined by testing drug amount in the supernatant after deproteinization, and the total drug amount could be determined following a treatment with acid to cleave all the conjugate and to liberate doxorubicin (Unger et al., 2007) . The same procedures were followed to assay samples from the group treated with . doxorubicin.
Drug penetration assay
The penetration of fluorescent drugs (DOX, INNO 206, Cy7-HSA-DOX and Cy7-HSA-INNO 206) into MCTSs or tumour tissue was analysed under a laser scanning confocal microscope (Live 5 and LSM 700, Carl Zeiss, Oberkochen, Germany). MCTSs were collected after different periods of incubation with drug and the drug fluorescence was measured. Z-stack images were obtained by scanning a spheroid every 10 μm from the top of the spheroid with a total scan range of 200 μm in depth. A plane approximately halfway through the z-stack image was chosen for quantification, and the fluorescence intensities were plotted against the radius.
The tumours were collected and were immediately embedded in OCT compound, frozen and stored at À80°C. Next, 10-μm-thick cryosections were cut at approximately 100 μm intervals for each tumour and mounted on glass slides. Fluorescence was imaged using the same objective (10X and 0.5A), and the fluorescence intensities of doxorubicin in the tumour cryostat sections were plotted against the intersecting line.
Oxygen level in MCTSs and tumour mass
Ru(dpp) and Ru(dpp) 3 (PF 6 ) 2 have been widely used as viable probes for the luminescent detection and quantification of oxygen in MCTSs (Kasinskas et al., 2014) . MCTSs were treated with Ru(dpp) 3 (PF 6 ) 2 (Sigma-Aldrich) overnight at 37°C, and the fluorescence was measured on an inverted fluorescence microscope (λ ex = 455 nm, λ em = 613 nm).
The Hypoxyprobe ™ -1 Plus kit (Millipore) is a two-step immunohistochemical assay for hypoxia in rodent tissues (Varia et al., 1998) . Xenograft mice were injected with 60 mg·kg À1 pimonidazole hydrochloride. After 30 min, the mice were killed and the tumours were excised. The excised tumours were fixed in 4% paraformaldehyde, embedded in OCT compound, frozen at À80°C, cut into 10-μm-thick slices and then mounted on glass slides. After being blocked with 5% BSA, the slide was treated with anti-hypoxyprobe combined with FITC at a concentration of 1:50 at 37°C for 2 h. Then, the fluorescence was visualized with an inverted fluorescence microscope (λ ex = 495 nm, λ em = 530 nm).
Mathematical model of drug penetration
To distinguish between the intercellular and intracellular compartments, an individual-cell-based mathematical model based on MCTS was developed in our study. The MCTS was considered as a regular spheroid containing a series of cell layers separated by small intercellular spaces. The number of cell layers was determined by staining the spheroid section with H&E. The intracellular accumulation profiles were modelled using compartment models, and the intercellular penetration was described by ODEs. This model allowed the drug to accumulate in cells in different layers when penetrating within the cell layers.
In addition, the cells in the same layer were assumed to have similar physiological status and drug pharmacokinetic profiles.
A brief schematic presentation of this model is shown in Supporting Information Fig. S1 . An integrated mathematical model was constructed as follows:
Cell layer n:
Cell layer 2:
Cell layer 1:
where n represents the cell layer number from the centre of the spheroid to the periphery; m is the total number of cell layers; D is the administered drug dose; D n represents the drug exposure dose outside the n th cell layer; C n is the intracellular drug concentration in the n th cell layer; K n and P n describe the transport rate constant and the permeability coefficients across the membranes of the cells in the n th layer respectively; K pn is the drug penetration rate within the intercellular space of the n th cell layer; X mn is the intracellular drug concentration threshold in the n th cell layer; dCn dt represents the intracellular retention rate in the n th cell layer; and dDn dt is the intercellular diffusion rate. Differential equations were solved using FORCAL V9.0, and all the parameters were estimated using MATLAB 2009 software.
The translation from fluorescence intensity to intracellular concentration
According to the linear relationship between the intracellular drug concentration and the fluorescence intensity (see Supporting Information Fig. S2 ), the translation from fluorescence intensity to intracellular drug concentration could be processed using the mass balance law. In addition, the equations are shown as follows:
where F n represents the florescence intensity of the n th cell layer; V cell and D cell represent the volume and the diameter of a single cell respectively; N n is the cell count in the n th cell layer; and M spheroid represents the moles of drugs in the whole MCTS.
The translation from in vitro to in vivo
The drug concentration in the tumour in vivo is dependent on a complex kinetic profile and involves a variety of biochemical, mechanical and biophysical factors, which make this process complex and difficult to comprehensively describe by mathematical modelling (Kim et al., 2013) . Thus, we simplified the process by making several reasonable assumptions and highlighted intracellular diffusion and intracellular accumulation.
1) The vessel density in HepG2 tumours was only 0.01% . Thus, the drug delivery profile in this tumour could be regarded as drug delivery to the avascular regions. 2) Intercellular transport of low MW drugs (MW from 76 to 1255) was diffusion-dominated (Goodman et al., 2008) , and the diffusion coefficient (K 0 pn ) in tumour mass for free extracellular doxorubicin is calculated to be 0.568 (Swabb et al., 1974; Eikenberry, 2009). 3) Intracellular doxorubicin transport was highly associated with the physiological status of tumour cells (Fu et al., 2015) . HepG2 MCTSs with a diameter of 500 μm displayed similar physiochemical gradients to avascular tumours of a certain size, making it reasonable to assume the similarity between the intracellular accumulation profiles of doxorubicin in the HepG2 MCTSs and their xenograft tumour mass (Mehta et al., 2012; Jain, 2013; Nath and Devi, 2016) . Similar to the K n in MCTS, the transport rate constant (K 0 n Þ in tumour mass was constant across all cell layers. The relationship of P n and X mn /D with n in the MCTS could be fitted according to the functions: for MCTS, the drug supply for the tumour mass depended on the plasma concentration, which was constantly changing (Steuperaert et al., 2017) . Thus, the intercellular diffusion rate outside the n th cell layer of the tumour mass is described as After determining the parameters, we could calculate drug concentration in different cell layer (C 0 n ) using the following function:
Data and statistical analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . Data were expressed as the mean ± SEM, with n indicating the number of animals used in vivo experiment or samples used in vitro experiments. First, each continuous variable was analysed for its normal distribution using the Kolmogorov-Smirnov test, and then statistical analysis was performed using two-tailed Student's t-test and one-way ANOVA. Differences were considered significant at P < 0.05. Statistical data analysis was performed using GraphPad Prism 5.
Materials
Doxorubicin was purchased from Chemlin Chemical Industry (Jiangsu, China). LY335979 was purchased from Selleckchem (Houston, TX, USA). YC-1 were purchased from Sigma-Aldrich (St. Louis, MO, USA). Methanol and acetonitrile were purchased from Sigma-Aldrich (St. Louis, MO, USA). HSA and Cy7-decorated HSA were purchased from Bioss (Beijing, China). Deionized water was purified using a Milli-Q system (Millipore, Milford, MA, USA) and was used throughout. INNO 206 was purchased from MedChem Express (Monmouth Junction, NJ, USA).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/2016 (Alexander et al., 2015a,b) .
Results
Morphology and physiological features of MCTS
After 7 days of culture, HepG2 cells aggregated as tightly compact spheroids ( Figure 1A , B) with a defined margin and a precisely controlled size (500 μm in diameter). For more than 85% of the spheroids, the ratio of the minor axis to the major axis was greater than 0.9 ( Figure 1D ). Furthermore, the flat areas of the MCTSs were concentrated in a narrow range from 0.06 to 0.07 mm 2 ( Figure 1E ), and the cell count was approximately 2:1Ã10 5 per spheroid ( Figure 1F ). The cells in the central region of the MCTS had already shrunk, and their cellular membranes were broken, whereas the cells in the periphery BJP J Liu et al.
Figure 1
Morphology and physiological features of MCTSs. HepG2 MCTSs were developed after culturing 7500 HepG2 cells for 7 days. A phase contrast image (A) and scanning electron microscopy image (B) were shown. After the MCTS was cut along the centre axis, its inner structure, and the physiological status of cells in the central and peripheral regions, were revealed (C). The frequency and cumulative frequency of the diameter ratio (D, n = 60) and the frequency distribution of the flat area (E, n = 60) were also statistically analysed. The numbers of cell layers in each MCTS was determined in five independent experiments (F, n = 5). The distribution of staining with H&E or Ki-67 and of the presence of doxorubicin in the MCTS and tumour mass are shown in (G), and the fluorescence intensities are plotted in (H and I).
Doxorubicin-related delivery in avascular regions BJP were growing and possessed intact membranes ( Figure 1C ). H&E and Ki67 staining results also showed the differential physiological status in the different regions of the MCTSs. Thus; cells in the periphery were highly proliferative, but the cells in the central region were quiescent or necrotic, which was similar to the distribution of physiological status in the tumour mass ( Figure 1G ). Furthermore, drug penetration in the MCTSs was also similar to that in the tumour mass ( Figure 1G ). In a plot of the semi-quantitative fluorescence intensity of the drugs against the depth in the MCTS ( Figure 1H ) and tumour mass ( Figure 1I ), decreased drug retention from the periphery to the centre was observed in both groups. In addition, based on the diameter of a single cell (7.8 μm), the number of cell layers in a MCTS could reach 32 ( Figure 1G )
Penetration profile of doxorubicin in MCTS
The kinetic and dynamic profiles of doxorubicin were tested on the validated HepG2 MCTSs. The IC 50 increased 10.51-fold from SLC to MCTSs (Figure 2A) , and the X max decreased 2.57-fold ( Figure 2B ). Monitoring the autofluorescence of doxorubicin revealed that the fluorescent signal was found mainly in the periphery of the MCTS and that the fluorescence intensity became weaker, closer to the MCTS core. This profile was independent of the concentration of drug used ( Figure 2C ). A plot of the semi-quantitative fluorescence intensities against the depth into the MCTS is shown in Figure 2D . The kinetics of drug penetration in different cell layers (32 accumulation curves for 32 cell layers) were simulated using the individual-cell-based mathematical model following the fluorescence intensityintracellular concentration translation. The accuracy of this model was validated (see Supporting Information Fig. S3a-d) , and its descriptive skill was further verified via a favourable simulation of the kinetic profiles in different cells layers when the concentration of doxorubicin used was 5 μM (see Supporting Information Fig. S3e-j) . Intracellular drug accumulation was positively correlated with the drug exposure dose, and the differences in accumulation between the cell layers were similar in the two doxorubicin administration groups ( Figure 2E ): the slopes and maxima of the accumulation curve for central layer cells (n = 1) were much lower than those of the accumulative curve for peripheral layer cells (n = 32). All the individual kinetics parameters are shown in Supporting Information Table S1 . K n could be considered as a constant (0.168 ± 0.027), and the value of K pn fluctuated around 82.15 ( Figure 2F ). In both drug exposure groups, P n gradually increased between cell layers (i.e. as n increased) ( Figure 2F ). X m reflected the saturation amount of intracellular accumulation, which was dependent on both the drug exposure dose and cell physiological status. X m had a linear relationship with the drug exposure dose (see Supporting Information Fig. S3k-l) ; thus, X mn /D was used here to reflect the effect of cells. As shown in Figure 2F , X mn /D gradually increased from the centre cells (n = 1) to the periphery cells (n = 32), and the value in the first cell layer was less than 40% of that in 32th cell layer. In addition, the retention rates ( dCn dt ) and diffusion rates ( dDn dt ) were calculated according to these parameters ( Figure 2G ). In the groups exposed to 2 or 10 μM, the diffusion rates remained significantly higher than the corresponding retention rates in all cell layers.
Different effects of HIF-1α or P-gp inhibitors on doxorubicin penetration in MCTS
As shown in Figure 3A , the oxygen level in the MCTS decreased from the periphery to the centre, whereas P-glycoprotein (P-gp) expression increased. This phenomenon was also demonstrated in the tumour mass. The P-gp inhibitor LY335979 and the HIF-1α inhibitor YC-1 significantly increased drug sensitivity ( Figure 3B ) and intracellular drug accumulation ( Figure 3C ) in the MCTS. The penetration profile of doxorubicin in different cell layers of the MCTS after co-administration with YC-1 or LY335979 is shown in Figure 3D . LY335979 increased the rate and extent of drug accumulation in peripheral cells but had little effect on the central cells, whereas YC-1 exhibited enhancing effect on peripheral cells and, in particular, on central cells. This phenomenon was also reflected by the kinetic parameters shown in Figure 3E : after co-administration with YC-1, the slopes of the lines for X mn /D and P n became quite smooth, whereas for the LY335979 group, the slopes became steeper because of the significant increases in the periphery. In addition, the retention rates ( dCn dt ) and diffusion rates ( dDn dt ) were calculated using the above parameters ( Figure 3F ). 
Figure 2
Drug sensitivity, retention and penetration kinetics of doxorubicin in MCTSs. Sensitivities of MCTSs and SLC to doxorubicin (DOX) were determined (A). Retention of doxorubicin in MCTSs and SLC is shown in (B), and drug penetration in MCTSs after incubation with doxorubicin (2 or 10 μM ) shown in (C). The fluorescence intensities were plotted (D), and drug accumulation in different cell layers was calculated (E). Kinetic parameters were further fitted and calculated using mathematical modelling (F). Intercellular diffusion rate and intracellular retention rate were calculated and are shown in (G).
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After co-administration with LY335979, the retention rates were markedly increased and remained higher than the diffusion rates at every time point. By contrast, YC-1 did not affect the diffusion rates, which remained above 10 times greater than the retention rates.
Different effects of hypoxia and P-gp inhibitors on doxorubicin penetration in tumour mass
Vessel distribution was determined using CD31 staining. In the tumour mass derived from HepG2 cells, vessels were present mainly in the periphery, not in the centre ( Figure 4A ). As shown in Figure 4B , C, only YC-1 inhibited the expression of HIF-1α and its downstream genes, especially P-gp, in the tumour mass, whereas LY335979 had no effect. After coadministration with LY335979 or YC-1, the tumour/plasma ratio of the drug concentration was increased by 1.25-fold or 1.36-fold respectively ( Figure 4D ). The centre section of the tumour tissue was divided into six concentric regions with the centre as the reference. The representative images showed that doxorubicin primarily accumulated at the peripheral region with a decreasing concentration towards the centre and that LY335979 could increase the fluorescence signals in the 66.68-100% (periphery) radius part. By contrast, YC-1 mainly affected the 0-50% radius (centre) part ( Figure 4F) . A plot of the fluorescence intensities against the distance is shown in Figure 4E . The simulated kinetic profiles in the tumour mass, which were predicted according to the translation model from in vitro to in vivo ( Figure 4G ), were significantly correlated with the experimental data ( Figure 4H , Pearson coefficient r = 0.6729 and P = 0.0165).
Penetration profile of HSA-decorated INNO 206 in MCTS
Between the SLC and MCTS models, HSA-DOX showed no significant differences in efficacy. However, a difference was observed between the two models when both were exposed to HSA-INNO 206. Specifically, HSA-INNO 206 had more efficacy in the MCTS model than in the SLC model ( Figure 5A ). In the MCTS model, the intracellular accumulation rates and the extent of unbound drug and total drug in HSA-INNO 206 group kept increasing with the time of drug exposure, and both were significantly higher Figure 3 Different effects of an HIF-1α inhibitor and a P-gp inhibitor on doxorubicin penetration in the MCTS. P-gp expression and hypoxia level in the MCTS and tumour mass were studied (A). Drug sensitivities after co-administration with a P-gp inhibitor (LY335979, 10 μM) or an HIF-1α inhibitor (YC-1, 5 μM) were assayed (B), and drug retention was also measured (C). In addition, drug accumulation in different cell layers was further analysed (D), and the parameter changes were also tested (E). Intercellular diffusion rates and intracellular retention rates were calculated according to the parameters (F).
Figure 4
Different effects of an HIF-1α and a P-gp inhibitor on doxorubicin in the tumour mass, ex vivo. Figure 5C ), and the fluorescence intensities were plotted against the radius ( Figure 5D ). As the incubation time was prolonged, the fluorescence intensity became stronger, and the slopes of the intensity curves became steeper but were still much less than those of doxorubicin. HSA could also be detected through the conjugation of a fluorescent group, Cy7. Figure 5E shows that the majority of HSA-DOX was present as a conjugate in the peripheral region with a merging rate of up to 66%, whereas considerable unbound drug was present in the HSA-INNO 206 group, especially in the centre region, with a merging rate of only 28% ( Figure 5F ). The pH value in the MCTS decreased from the periphery to the centre, although treatment with YC-1 lessened this pH difference ( Figure 5G ). The hypoxiadependent acidic micro-environment in MCTS induced the release of unbound doxorubicin from HSA-INNO 206 ( Figure 5H ). Compared with DOX, INNO 206 and the HSA-decorated drug were less influenced by the efflux pump P-gp ( Figure 5I ). The kinetic profiles of intracellular accumulation in different cell layers were plotted in Figure 5J , and the kinetic parameters were further simulated ( Figure 5K ). Accumulating curves in HSA-INNO 206 group were all higher than the corresponding curves in HSA-DOX group. X mn /D was enhanced in HSA-INNO 206 group, and the slope was less steep. There were no significant differences between these two groups for P n , K n and K pn . The retention rates were higher in HSA-INNO 206 group while the diffusion rates were similar ( Figure 5L ). For HSA-INNO 206, the diffusion rates were lower than the retention rates at 1, 4, 8 and 16 h, but it was higher from 24 to 72 h.
Penetration profile of INNO 206 in the tumour mass
The penetration profile of INNO 206 was validated in a xenograft tumour model. Comparing the INNO 206 administration group with the doxorubicin administration group revealed a significant decrease in the unbound doxorubicin plasma concentration ( Figure 6A ), whereas total drug concentration was markedly increased ( Figure 6B ), resulting in a smaller plasma AUC of unbound doxorubicin and a larger AUC of total drug ( Figure 6C ). The amounts and the AUCs of unbound doxorubicin and total drug in tumour tissue were both much smaller in INNO 206 group than in the doxorubicin group ( Figure 6D-F) . At 1 h post-drug administration, the fluorescence intensity in the doxorubicin group was higher than that in in the group treated with INNO 206, whereas at 48 h post-drug administration, the opposite tendency was observed. At two time points, the fluorescence intensity difference between the peripheral part and central part was much smaller in the INNO 206 group than in the doxorubicin group (Figure 6G -J).
Discussion
Drug delivery (penetration) in the avascular regions of tumours is one of the main barriers for the efficacy of doxorubicin -related therapy (Bolouri, 2015; Khawar et al., 2015) . This process is governed by two linked processes: intercellular diffusion and intracellular retention. However, there is currently no appropriate method for evaluating the intercellular and intracellular components separately or the kinetic interaction between the two. To solve this problem, an innovative translation model for drug penetration based on MCTS was developed (see Supporting Information Fig.-S1) . Unlike other reported mathematical models, our model treated cells in different layers as different compartments and highlighted their different drug disposition kinetics. Thus, this model was much more suitable for drug delivery evaluation in the avascular regions of tumours (Kim et al., 2013) and enabled further analysis of the interaction between intercellular diffusion and intracellular retention.
The MCTS is one of the most well-characterized organotypic model of cancer and one of the most commonly used models for drug penetration in avascular tumours (Nath and Devi, 2016; Winner et al., 2016) . Here, HepG2 cells were chosen because its MCTS exhibits the same physiological status ( Figure 1G ), microenvironments ( Figures 3A and 5G ) and doxorubicin penetration profile ( Figure 1G-I) as is found in tumour tissue. Furthermore, the vessel density in HepG2 xenograft tumours is much smaller than that in xenograft tumours derived from other cell lines , and the vascular structure was only detected at the very peripheral edge of its xenograft-bearing tumour ( Figure 4A ), rendering it quite suitable for evaluating drug delivery (penetration) in the avascular regions. In HepG2 MCTSs, doxorubicin intracellular accumulation decreased from the periphery to the centre. Additionally, compared with SLC, drug cytotoxicity and retention were lower, confirming the important role of delivery profile in the avascular regions of tumours on the final kinetic and dynamic results (Figure 2A-D) . This inhomogeneous distribution was also detected in the tumour mass ( Figure 4E, F) . The intracellular accumulation profile was determined through two aspects: the drug supply outside the cell and the transport profile across the cell. The high but constant value of K pn indicated that the intercellular diffusion of doxorubicin was very rapid and uniform across all cell layers ( Figure 2F ). This result was consistent with previous reports indicating that the intercellular movement of small-sized drugs (12-30 nm) was not hindered (Popovic et al., 2010; Cabral et al., 2011) . Furthermore, the intercellular diffusion rate ( ∂Dn ∂t ) of doxorubicin was over eightfold greater than the drug retention rate ( dCn dt ), indicating that the doxorubicin concentration outside the different cells layers was sufficient and therefore was not the main reason for the inhomogeneous penetration of doxorubicin ( Figure 2G ). The fold change from intercellular diffusion rate to drug retention rate was similar in the 2 and 10 μM administration groups, indicating that the balance between these two rates was independent of the drug exposure dose outside the MCTS. K n describes the passive transport of doxorubicin and can also be regarded as a constant parameter here, indicating that the passive transport of doxorubicin across different cell layers was almost the same and thus was also not the main reason for its inhomogeneous penetration ( Figure 2F ). X mn /D and P n mainly represent the active transport of doxorubicin and continuously decreased from the periphery to the centre ( Figure 2F ), indicating that active transport is responsible for the inhomogeneous penetration of doxorubicin.
HepG2 MCTS growth caused an oxygen gradient to form, resulting in hypoxia region in the centre and normoxia regions on the periphery. The hypoxia at the centre induced the expression of P-gp (see Supporting Information Fig.  S4a-b) and finally effected an inhomogeneous distribution of P-gp, which was increased from the periphery to the centre ( Figure 3A) . This inhomogeneity was also demonstrated in the tumour mass. Studies based on SLC indicated that hypoxia-induced high P-gp expression was negatively correlated with the values of X m /D (see Supporting Information- Fig. S4 ) (Zhang et al., 2012) . Thus, we postulated that hypoxia-induced P-gp expression was the main cause of the inhomogeneous doxorubicin accumulation profile in the MCTS. Oshikata et al. (2011) also reported P-gp as the main cause for the higher IC 50 of doxorubicin in MCTSs. Coadministering either an HIF-1α inhibitor (YC-1) or a P-gp inhibitor (LY335979) significantly increased doxorubicin sensitivity and intracellular accumulation ( Figure 3B, C) ; while their influence on doxorubicin distribution was different,as only YC-1 optimized the distribution homogeneity ( Figure 3D, E) . Theoretically, LY335979 could optimize the accumulation profile in both the periphery and centre because of its non-specific inhibition of the P-gp protein. However, after LY335979 inhibited P-gp, the drug retention rate in the peripheral cells was significantly increased (increased P n and X m /D, Figure 3E ) and became much higher than the diffusion rate ( Figure 3F ), causing an insufficient doxorubicin supply outside the central cells (decreased K pn , Figure 3E ). Because the limitation on the central cells changed from active transport to extracellular drug supply, inhibition of P-gp by LY335979 provided no enhancements in these cells. This result partly explained the limited clinical outcome of P-gp inhibitors (Goldman, 2003; Gandhi et al., 2007) . The direct target of YC-1 is HIF-1α, which was specifically expressed in the inner hypoxia region. Therefore, the improvements provided by YC-1 were much more evident in the centre ( Figure 3E ). In addition, YC-1 had no influence on the intercellular diffusion rate ( Figure 3F ). Therefore, YC-1 effectively improved the homogeneity of doxorubicin distribution. These differential regulation effects of penetration were also validated in the xenograft tumour tissue (Figure 4) . Although a scaling analysis had previously suggested that only if the diffusion rate was greater than the cell internalization rate, then the intracellular retention could not be influenced by changing intercellular motion (Thurber et al., 2008a,b) , there is still no way to quantitatively calculate these two processes. Our model addressed this problem and, for the first time, quantitatively affirmed the different effects on doxorubicin-related delivery by a P-gp inhibitor and a hypoxia inhibitor.
To evaluate the applicability of our study to doxorubicin-related molecules, we chose an experimental doxorubicin derivative, which is in Phase II clinical trials, INNO 206, as an example. INNO 206, which is immediately converted into an albumin-bound form in vivo, can be regarded as a promising example of a pH-responsive formulation (Graeser et al., 2010; Mita et al., 2015; Chawla et al., 2015a,b (Figures 2A and  6A ), indicating that drug delivery in the avascular regions played important role in its greater cytotoxicity. The better penetration profile of HAS-INNO 206 was validated in the MCTS, and the detailed mechanisms were elucidated. On the one hand, both structural optimization from doxorubicin to INNO 206 and HSA decoration could help to block efflux by P-gp ( Figure 5I ), thus minimizing the difference in active transport between the central cells and peripheral cells in periphery. On the other hand, the hypoxia-related acidic micro-environment could promote the release of unbound doxorubicin from HSA-INNO 206 ( Figure 5G, H) , accelerating intercellular diffusion and intracellular accumulation ( Figure 5B ). The diffusion rate became larger than the retention rate after a long incubation with HSA-INNO 206 (48-72 h, Figure 5L ). The improved penetration was further validated in the HepG2 tumour-bearing model. The fluorescence intensity differences between the periphery and the centre were much smaller in in the group treated with INNO 206 at both 1 h (short-time point) and 48 h (long-time point) after drug administration ( Figure 6G-J) . Even though, in contrast to the results from the MCTS (Figure 5B ), the released unbound doxorubicin and total drug tumour accumulation were lower in the INNO 206 group, the penetration advantage was still observed in the tumour mass. This result further indicated that the penetration homogeneity in an avascular system was mainly dependent on delivery balance, not the drug supply profile outside the avascular region, which is consistent with our findings from the kinetic parameters assay.
In summary, we built a mathematical model that quantitatively described the penetration kinetic profile of doxorubicin-related delivery in the avascular regions of tumours and that served as a quantitative screening method for changes in that delivery. By summarizing the correlation between kinetic features and distributing homogeneity, we further dveleoped a kinetic rule for changing doxorubicinrelated delivery in avascular regions (Figure 7) . However, considering the feasibility of the quantitative analysis of intercellular diffusion and intracellular retention in each cell layer, we made some specific assumptions in our mathematical model to reduce the complexity of the computational calculations. These assumptions, which included disregarding the kinetic profile of cell proliferation and growth during drug administration and the irregular stereo-chemical structure of tumour tissue, compromised the quantitative descriptive ability for actual in vivo drug penetration. Thus, only the relative penetration profile in tumour tissue was simulated and predicted in this study. Although there are still numerous challenges to be overcome, our developed model is still a promising and useful model for evaluating and regulating doxorubicin-related penetration in the avascular regions of tumours.
Figure 7
Scheme for evaluating and regulating doxorubicin delivery in the avascular regions of tumours based on the MCTS and translation model. Figure S1 Mathematical model for drug diffusion and retention in multicellular spheroid. Figure S2 The linear relationship between fluorescence intensity and intracellular accumulation of DOX. HepG2 SLC were incubated with 1, 2, 5, 10, 20, 30 μM doxorubicin and the fluorescence were imaged at 2 hours post drug administration (A). The average fluorescence intensity in each image was semi-quantified and their relationship with the quantified intracellular concentration was also studied (B). Figure S3 Validation of mathematic model. The simulated curves and experimental data after 2 μM and 10 μM doxorubicin administration were fitted (A and B) . The correlation between calculate data and experiment data was analysed (C) and the residuals were plotted (D). Drug distribution (E), fluorescence intensity (F) and drug accumulation (G) after 5 μM doxorubicin administration were shown and they were highly coincided with the predicted curve based on kinetic parameters (H) which was validated by linear correction assay (I) and residual assay (J). HepG2 SLC were incubated with 1, 2, 5, 10 μM DOX. Time-course analysis of the intracellular accumulation was plotted (K) and the linear regression between X m and drug exposure amount was tested (L). Figure S4 Hypoxia changed the pharmacokinetic and pharmacodynamic profile of doxorubicin by inducing P-gp expression. Along with the culture schedule of MCTS, the P-gp expression was gradually increased (A) and it could be significantly decreased by the HIF-1α inhibitor, YC-1 (B). The values of Xm/D were compared between normal condition group and hypoxia condition group (C). Hypoxia could induce P-gp (MDR1) expression and YC-1 could reverse such induction (D). The changes of intracellular accumulation profile (E and F) and drug sensitives (G and H) after combined administration with LY335797 (10 μM) and YC-1(5 μM) were studied. Table S1 The kinetic parameters of doxorubicin penetration in MCTS.
